Impact of a Genomic Test on Treatment Decision in a Predominantly African American Population With Favorable-Risk Prostate Cancer: A Randomized Trial.

Although the power to detect a significant increase in AS was limited by high baseline acceptance, we observed a marginally significant decrease in AS adoption among the GPS group, largely because of men with low intermediate risk who had GPS results consistent with a higher NCCN risk level.

also in 26,082 other papers